3 results
Primary: Antiviral efficacy of dolutagravir in combination with Kivexa (abacavir en lamivudine) after 48 weeks of treatment in comparison with Atripla (tenofovir, emtricitabine and efavirenz). Secondary: Antiviral efficacy after 96 and 144 weeks,…
It is expected that LF111 will offer benefits to adults in the form of efficacy similar to COCPs, absence of estrogen-related risks, reduced tendency to weight gain and extended dosing window. It is likely that adolescents will share these benefits…
7.1 Primary objectiveThe primary objective of the study is to assess the attitude towards the use of the MedRing 7.2 Secondary objectiveThe secondary objectives of the study are to assess device related adverse events, device damage and physician…